NorthStar Medical Technologies signs letter of intent with Clarity Pharmaceuticals to supply therapeutic radioisotope copper-67

Press releases may be edited for formatting or style | February 11, 2020 Molecular Imaging

About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.

Back to HCB News

Your Centrifuge Specialty Store

Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576



You Must Be Logged In To Post A Comment Sign In If you've already created an account, use your email address and password to sign in using the form below. Login Problems: Click here if you are having login issues. Email address: Password: Forgot your password? Login Problems? View our Legal Notice and Privacy Notice Register Registration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now!

Molecular Imaging Homepage

NorthStar Medical Radioisotopes, LLC enters clinical supply agreement to support Clarity Cu-67 SAR-bisPSMA trials

SHINE Technologies, LLC announces submission of FDA Drug Master File for non-carrier-added lutetium-177

PanTera signs a second agreement for the supply of actinium-225

Radioguided surgery accurately detects and removes metastatic lymph nodes in newly diagnosed prostate cancer patients

Virtua Health installs innovative GE HealthCare systems to advance cardiac imaging in southern New Jersey

UT Health Science Center researchers awarded $20 million to develop new radiopharmaceutical cancer therapies

Lumicell announces data showing LUMISIGHT’s ability to detect tumors metastasized to multiple organs in the peritoneum

Fusion Pharmaceuticals enters license agreement with Heidelberg U, Euratom for actinium-based PSMA targeted radiotherapy

PanTera signs agreement with Bayer for the supply of actinium-225

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Over 150 New York Auctions End Today - Bid Now
Over 1050 Total Lots Up For Auction at Two Locations - MA 04/30, NJ Cleansweep 05/02